IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
IO Biotech, Inc. (IOBT)
Company Research
Source: GlobeNewswire
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., and be a member of the company’s executive team, effective immediately. “We are very excited to welcome Faiçal to IO Biotech,” said Dr. Zocca. “His deep experience in business development with proven ability to execute strategic transactions will be invaluable as we look at opportunities to advance our wholly owned proprietary T-Win platform. The coming months will be a critical period for the deve
Show less
Read more
Impact Snapshot
Event Time:
IOBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOBT alerts
High impacting IO Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
IOBT
News
- IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness [Yahoo! Finance]Yahoo! Finance
- IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessGlobeNewswire
- IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103GlobeNewswire
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
IOBT
Earnings
- 11/13/23 - Beat
IOBT
Analyst Actions
- 3/6/24 - HC Wainwright
IOBT
Sec Filings
- 4/26/24 - Form 8-K
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- IOBT's page on the SEC website